Verona Pharma Stock Price, News & Analysis

Verona Pharma plc (Nasdaq: VRNA) announces the appointment of Mr. James Brady as a Non-Executive Director, enhancing its board with his extensive experience in the biopharmaceutical industry. Brady's career spans over 30 years at AstraZeneca, including his role as Chief Financial Officer of MedImmune, contributing to significant product development. Concurrently, Dr. Andrew Sinclair will step down from the board after the Annual General Meeting on April 27, 2022. Verona Pharma is progressing its commercialization plans for ensifentrine, a novel respiratory therapy.

Verona Pharma (VRNA) reported financial results for Q4 and full year 2021, highlighting significant progress in the Phase 3 ENHANCE program aimed at COPD treatment. Enrollment is complete for over 800 subjects in ENHANCE-2 and approximately 400 in ENHANCE-1. Positive safety results from a TQT study were disclosed, supporting a potential NDA submission in H1 2023. Financially, the company noted a revenue of $40 million from the Nuance agreement, a net loss of $55.6 million for the year, and a cash position of $148.4 million as of December 31, 2021.

Ligand Pharmaceuticals (NASDAQ: LGND) reported strong financial results for Q4 and the full year 2021, with total revenues of $72.5 million in Q4, up from $70.0 million in 2020, and $277.1 million for the year, a significant increase from $186.4 million in 2020. Royalties rose to $17.6 million in Q4, largely due to the Pelican platform. However, net income for Q4 was a loss of $5.0 million compared to a profit of $5.8 million the previous year. Ligand plans to spin off its OmniAb business, expected to generate substantial growth, and provided guidance for 2022 revenues of $147 million to $172 million.

Verona Pharma plc (Nasdaq: VRNA) will announce its fourth quarter and full year financial results for 2021 on March 3, 2022. The company, focused on innovative therapies for respiratory diseases, will host a conference call at 9:00 a.m. EST to discuss the results and corporate updates. Interested participants can join via specified phone numbers or a live webcast available on the company's website. Verona Pharma is advancing its product candidate, ensifentrine, currently in Phase 3 and Phase 2 clinical trials, aiming to offer unique treatment options for COPD and other respiratory conditions.

Verona Pharma, a clinical-stage biopharmaceutical company, has completed the enrollment of over 800 subjects in its Phase 3 ENHANCE-2 trial, which evaluates ensifentrine for chronic obstructive pulmonary disease (COPD) maintenance treatment. The top-line data is expected in the third quarter of 2022. CEO David Zaccardelli noted that reaching this milestone during the ongoing pandemic is significant. The trial aims to demonstrate the efficacy of ensifentrine, which combines bronchodilator and anti-inflammatory effects, in improving lung function and quality of life for COPD patients.

Verona Pharma (Nasdaq: VRNA) has completed screening for the ENHANCE-2 trial, enrolling 788 subjects with full enrollment expected by January's end. The Phase 3 program focuses on ensuring ensifentrine, a novel nebulized treatment for chronic obstructive pulmonary disease (COPD), shows efficacy and safety. Top-line data is anticipated in 2022, potentially leading to a New Drug Application with the FDA in early 2023. As of December 31, 2021, the company reported $148.4 million in cash, sufficient to cover operations through at least 2023.

Verona Pharma (Nasdaq: VRNA) announced that David Zaccardelli, Pharm. D., the CEO, will present an overview of the company at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand from 7:00 AM EST / 12:00 PM GMT on January 10, 2022. Interested parties can access a webcast of the event for 90 days via the company's website's Investors page. Verona Pharma focuses on developing innovative therapies for respiratory diseases, with its product candidate ensifentrine currently in Phase 3 development for COPD.

Verona Pharma has successfully completed a thorough QT study for its product candidate ensifentrine, showing no adverse effects on cardiac conduction in healthy individuals. This study is essential for the NDA submission for ensifentrine, aimed at treating COPD. The results will support the ongoing Phase 3 clinical trial program, ENHANCE, with expected data reporting in 2022. Ensifentrine, if approved, could become the first treatment combining bronchodilator and anti-inflammatory properties for respiratory diseases.

Verona Pharma reports its financial results for Q3 2021, revealing significant advancements in its ENHANCE Phase 3 clinical program for ensifentrine, targeting respiratory diseases. As of November 8, 2021, enrollment in ENHANCE-2 is approximately 90% complete, while the 48-week subset of ENHANCE-1 is about 95% enrolled. The company expects to conclude enrollment by year-end 2021 and release top-line data in mid-2022. Financially, revenues reached $40 million, supported by a new agreement with Nuance Pharma, and net profit improved to $11.1 million, a significant turnaround from a loss the previous year.